Company profile for SemaThera Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

SemaThera develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). SEMA 3A is a soluble protein that promotes vascular leakage and contributes to diabetes-related macular edema. Its levels are significantly elevated in the vitreous of patients with DME as well as in several other vascular diseases of the retina. Importantly.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
800-1 Westmount Square, Montreal, Québec Canada, H3Z 2P9
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmacompass.com/pdf/news/semathera-enters-into-a-research-collab-exclusive-license-agreement-roche-1619170836.pdf

PRESS RELEASE
22 Mar 2021

http://www.pmlive.com/pharma_news/news_charity_criticises_nhs_england_and_vertex_over_orkambi_access,_sema_scores_again,_nodthera_launched_1241815

A. McConaghie PMLIVE
25 Jun 2018

https://www.businesswire.com/news/home/20180321005604/en/SemaThera-Announces-2MUS-Financing-Licensing-Deal-China

BUSINESSWIRE
21 Mar 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty